{"id":"W2604245147","doi":"10.1200/jco.2012.30.15_suppl.e13602","title":"MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Erlotinib; Medicine; Rash; Adverse effect; Internal medicine; Pharmacodynamics; Pharmacology; Pharmacokinetics; Tyrosine-kinase inhibitor; Gastroenterology; Oncology; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000694059,0.0006789484,0.0008657661,0.0003995584,0.000200209,0.0005850063,0.0004836298,0.000471878,0.000913616],"category_scores_gemma":[0.0003580729,0.0003076817,0.0005956559,0.0004776303,0.000327593,0.0003331438,0.0003336335,0.0008058605,0.0002786663],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000599691,"about_ca_system_score_gemma":0.0006499732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006613781,"about_ca_topic_score_gemma":0.003011305,"domain_scores_codex":[0.9997881,0.00007768644,0.00001998592,0.00002945856,0.00003729263,0.00004743278],"domain_scores_gemma":[0.9998388,0.00002232989,0.00004424436,0.0000101964,0.000008237372,0.00007622164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.311145,0.02653251,0.05208078,0.002379357,0.001630568,0.002504284,0.0005903901,0.009553303,0.09810109,0.0004800827,0.009645897,0.4853567],"study_design_scores_gemma":[0.2208374,0.5975062,0.12099,0.0002059483,0.001550041,0.004763943,0.0002118529,0.005790137,0.02557052,0.0002708725,0.02221483,0.00008831081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927905,0.004180762,0.00030407,0.0002732225,0.00005196184,0.0004861208,0.0002858719,0.00005432752,0.001573087],"genre_scores_gemma":[0.9956337,0.001953012,0.0006556005,0.0002171337,0.00006041253,0.0001316311,0.0005259612,0.000006428805,0.0008160609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.000913616,"threshold_uncertainty_score":0.004351139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02280814110688999,"score_gpt":0.3525868577803213,"score_spread":0.3297787166734313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}